TapewireFind a company

organization · Reporting owner

Atlas Venture Associates Opportunity II, LP

Disclosed activity across 5 companies

Tapewire entity
83427
SEC CIK
0001935814

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Dyne Therapeutics, Inc.DYN · Entity 394810% ownerMarch 01, 2024March 05, 2024
Korro Bio, Inc.KRRO · Entity 638810% ownerApril 22, 2024April 23, 2024
Q32 Bio Inc.QTTB · Entity 559410% ownerMarch 25, 2024March 27, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,458,691 Reported balance After 2024-03-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-03-01 · Sale · Disposed 29,435 · Balance 1,458,691

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote847,388 Reported balance After 2024-03-01 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-03-01 · Sale · Disposed 17,099 · Balance 847,388

F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F5: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Korro Bio, Inc.

Report date April 22, 2024 · Filed April 23, 2024

Jointly reported with Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect195,074 Reported balance After 2024-04-22 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-04-22 · Purchase · Acquired 17,857 · Balance 195,074

F1: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect864,261 Reported balance Holding disclosure · report date 2024-03-25 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 864,261

F1: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy Atlas Venture Opportunity Fund I, L.P.503,296 Reported balance Holding disclosure · report date 2024-03-25 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 503,296

F2: Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy Atlas Venture Opportunity Fund II, L.P.724,549 Reported balance Holding disclosure · report date 2024-03-25 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 724,549

F3: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

F2: Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

F3: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2024-01-25. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,402,186 Reported balance After 2024-01-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-01-23 · Sale · Disposed 47,500 · Balance 1,402,186

F1: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote703,660 Reported balance After 2024-01-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-01-23 · Sale · Disposed 82,500 · Balance 703,660

F2: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote198,326 Reported balance After 2024-01-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2024-01-23 · Sale · Disposed 20,000 · Balance 198,326

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

F2: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any.

Section 16 reporting ended · disclosed 2025-02-10. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,886,293 Reported balance After 2025-02-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-02-10 · Conversion · Acquired 2,886,293 · Balance 2,886,293

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Atlas Venture Opportunity Fund II, L.P.807,727 Last balance in matching sequence After 2025-02-10 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 2 · 2025-02-10 · Conversion · Acquired 747,727 · Balance 747,727

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Row 3 · 2025-02-10 · Purchase · Acquired 60,000 · Balance 807,727

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Series Seed convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-02-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-02-10 · Conversion · Disposed 1,051,051 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series A convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-02-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-02-10 · Conversion · Disposed 1,806,317 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series B convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-02-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-02-10 · Conversion · Disposed 1,298,332 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series C convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-02-10 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-02-10 · Conversion · Disposed 61,463 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series C convertible preferred stockSEC Table II · derivative / convertible securityIndirectBy Atlas Venture Opportunity Fund II, L.P.0 Reported balance After 2025-02-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2025-02-10 · Conversion · Disposed 1,092,504 · Balance 0

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries C convertible preferred stock · Derivative 1,092,504 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 8

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 747,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries C convertible preferred stock · Derivative 61,463 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 7

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,068 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries B convertible preferred stock · Derivative 1,298,332 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 888,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries A convertible preferred stock · Derivative 1,806,317 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,236,271 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionSeries Seed convertible preferred stock · Derivative 1,051,051 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 719,355 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 PurchaseCommon Stock 60,000 $18.00 $1,080,000.00
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P.

Disclosed balance after: 807,727

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionCommon Stock 747,727 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P.

Disclosed balance after: 747,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 10, 2025 Filed Feb 10, 2025 21:05 UTC Sionna Therapeutics, Inc. SION · Entity 5996 ConversionCommon Stock 2,886,293 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,886,293

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.

F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
April 22, 2024 Filed Apr 23, 2024 17:23 UTC Korro Bio, Inc. KRRO · Entity 6388 PurchaseCommon Stock 17,857 $56.00 $999,992.00
Disclosure

SEC source: 0001415889-24-011385 · form4-04232024_090431.xml · nonDerivative · entry 1

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,074

F1 · ownership.direct: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 17:07 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 17,099 $30.05 $513,824.95
Disclosure

SEC source: 0001415889-24-006764 · form4-03052024_100352.xml · nonDerivative · entry 2

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 847,388

F4 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 17:07 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 29,435 $30.05 $884,521.75
Disclosure

SEC source: 0001415889-24-006764 · form4-03052024_100352.xml · nonDerivative · entry 1

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,458,691

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 210 $25.25 $5,302.50
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 18

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 864,487

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 13,109 $24.83 $325,496.47
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 17

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 864,697

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 360 $25.25 $9,090.00
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 16

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,488,126

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 22,567 $24.83 $560,338.61
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 15

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,488,486

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 2,430 $25.25 $61,357.50
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 14

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,698,091

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 152,244 $24.83 $3,780,218.52
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 13

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,700,521

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 2,216 $24.68 $54,690.88
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 12

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 877,806

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 23,505 $24.38 $573,051.90
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 11

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 880,022

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 3,821 $24.68 $94,302.28
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 10

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,511,053

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 40,455 $24.38 $986,292.90
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 9

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,514,874

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 25,779 $24.68 $636,225.72
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 8

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,852,765

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 272,923 $24.38 $6,653,862.74
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 7

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,878,544

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 5,580 $23.98 $133,808.40
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 903,527

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 11,736 $23.59 $276,852.24
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 909,107

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 9,603 $23.98 $230,279.94
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,555,329

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 20,205 $23.59 $476,635.95
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,564,932

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 64,783 $23.98 $1,553,496.34
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,151,467

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 136,312 $23.59 $3,215,600.08
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,216,250

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 13,738 $22.70 $311,852.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 920,843

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F10 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 23,648 $22.70 $536,809.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,585,137

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F8 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 159,542 $22.70 $3,621,603.40
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,352,562

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 22, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 119,360 $22.66 $2,704,697.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,512,104

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $23.1566 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 35,164 $23.14 $813,694.96
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,631,464

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7625 to $23.3899 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 149,337 $22.44 $3,351,122.28
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,666,628

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $22.72 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6).

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:31 UTC Disc Medicine, Inc. IRON · Entity 2273 SaleCommon Stock 20,000 $67.65 $1,353,000.00
Disclosure

SEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 3

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 198,326

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:31 UTC Disc Medicine, Inc. IRON · Entity 2273 SaleCommon Stock 82,500 $67.65 $5,581,125.00
Disclosure

SEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 703,660

F2 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:31 UTC Disc Medicine, Inc. IRON · Entity 2273 SaleCommon Stock 47,500 $67.65 $3,213,375.00
Disclosure

SEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,402,186

F1 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
December 12, 2022 Filed Dec 14, 2022 16:55 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 PurchaseCommon Stock 934,581 $10.70 $10,000,016.70
Disclosure

SEC source: 0001209191-22-061243 · doc4.xml · nonDerivative · entry 1

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 934,581

F1 · ownership.direct: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.